Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma

A 70-year-old man was diagnosed with multiple lung metastases from hepatocellular carcinoma, and lenvatinib was initiated. Three months later, the response was progressive disease. Sorafenib therapy as a second-line drug was started. Three months later, the lung metastases had shrunk. After the sora...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Atsuyuki, Aoki, Kentaro, Kawamura, Masahito, Yamaguchi, Daisuke, Kokuryu, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925274/
https://www.ncbi.nlm.nih.gov/pubmed/33518611
http://dx.doi.org/10.2169/internalmedicine.5552-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925274/
https://www.ncbi.nlm.nih.gov/pubmed/33518611
http://dx.doi.org/10.2169/internalmedicine.5552-20

Ejemplares similares